NASDAQ | DRNA

$5.25 - 0.02 (-0.380%)

3 month stock price graph

4:00 PM ET on Oct 19, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
Nov 7, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the third quarter ended...
Oct 31, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2016 financial results after market close on Monday, November 7, 2016. ...
Sep 26, 2016
Primary Hyperoxaluria Development Program Transitioned From DCR-PH1 to Subcutaneously Delivered GalXC Candidate DCR-PHXC Clinical Development Discontinued for DCR-MYC in Oncology Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DR...
Sep 6, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following investor conferences in September. ...
Aug 4, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the second quarter ende...
Jul 28, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2016 financial results after market close on Thursday, August 4, 2016. ...
Jun 29, 2016
Consistent, Potent and Durable Silencing of Multiple Disease-Driving Genes in Non-Human Primates Reported at Investor Day Initial GalXC Program on Track for First IND Filing in Late 2017 Live Webcast to Begin at 8:30 a.m. Eastern Time CAMBRIDGE, Mass.--(BUSINE...
Jun 15, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.D., former co-founder and chief medical officer of Civitas Therapeutics, Inc., to its board of ...
Jun 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference. The ...
May 13, 2016
Milestone for DsiRNA Therapeutic Follows Receipt of Orphan Drug Designation in US and EU CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase